K. Beckmann

2.8k total citations
38 papers, 2.1k citations indexed

About

K. Beckmann is a scholar working on Pathology and Forensic Medicine, Rheumatology and Oncology. According to data from OpenAlex, K. Beckmann has authored 38 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pathology and Forensic Medicine, 18 papers in Rheumatology and 11 papers in Oncology. Recurrent topics in K. Beckmann's work include Multiple Sclerosis Research Studies (32 papers), Systemic Lupus Erythematosus Research (12 papers) and Rheumatoid Arthritis Research and Therapies (7 papers). K. Beckmann is often cited by papers focused on Multiple Sclerosis Research Studies (32 papers), Systemic Lupus Erythematosus Research (12 papers) and Rheumatoid Arthritis Research and Therapies (7 papers). K. Beckmann collaborates with scholars based in Germany, United States and Canada. K. Beckmann's co-authors include Alan J. Thompson, Carlo Pozzilli, Chris H. Polman, Ludwig Kappos, Frank Dahlke, Rupert Sandbrink, Alyson J. Berliner, Robert Vitti, Anthony T. Reder and George C. Ebers and has published in prestigious journals such as PLoS ONE, Brain and Neurology.

In The Last Decade

K. Beckmann

36 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. Beckmann Germany 24 1.4k 655 576 552 534 38 2.1k
S. Anand Trip United Kingdom 17 1.2k 0.8× 386 0.6× 765 1.3× 430 0.8× 306 0.6× 34 1.8k
HP Hartung Germany 18 1.8k 1.3× 721 1.1× 90 0.2× 1.1k 2.0× 159 0.3× 58 2.3k
Fedor Heidenreich Germany 24 835 0.6× 316 0.5× 118 0.2× 666 1.2× 123 0.2× 49 2.1k
Joaquín Castilló Spain 22 1.4k 1.0× 510 0.8× 61 0.1× 644 1.2× 102 0.2× 48 1.7k
Kathleen Hawker United States 18 1.2k 0.9× 324 0.5× 43 0.1× 621 1.1× 179 0.3× 29 1.6k
Maureen A. Mealy United States 29 2.1k 1.5× 653 1.0× 312 0.5× 1.8k 3.2× 55 0.1× 60 2.5k
Joachim Havla Germany 20 936 0.7× 265 0.4× 136 0.2× 559 1.0× 61 0.1× 66 1.3k
Benjamin Brooks United States 9 1.9k 1.4× 653 1.0× 34 0.1× 958 1.7× 125 0.2× 14 2.3k
Elia Sechi Italy 25 971 0.7× 375 0.6× 61 0.1× 1.4k 2.6× 80 0.1× 93 2.0k
Catherine Agoropoulou Switzerland 5 1.6k 1.1× 347 0.5× 62 0.1× 536 1.0× 47 0.1× 7 2.2k

Countries citing papers authored by K. Beckmann

Since Specialization
Citations

This map shows the geographic impact of K. Beckmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Beckmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Beckmann more than expected).

Fields of papers citing papers by K. Beckmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Beckmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Beckmann. The network helps show where K. Beckmann may publish in the future.

Co-authorship network of co-authors of K. Beckmann

This figure shows the co-authorship network connecting the top 25 collaborators of K. Beckmann. A scholar is included among the top collaborators of K. Beckmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Beckmann. K. Beckmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hartung, Hans-Peter, Ludwig Kappos, Douglas S. Goodin, et al.. (2015). Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. Journal of Neurology. 262(11). 2466–2471. 3 indexed citations
2.
Beckmann, K., Volker Knappertz, Ludwig Kappos, et al.. (2014). Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study. European Neurology. 71(3-4). 173–179. 9 indexed citations
3.
Holz, Frank G., Johann Roider, Yuichiro Ogura, et al.. (2013). VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. British Journal of Ophthalmology. 97(3). 278–284. 181 indexed citations
4.
Lampl, Christian, Stefan Nagl, Barry G.W. Arnason, et al.. (2013). Efficacy and safety of interferon beta-1b sc in older RRMS patients—a posthoc analysis of the BEYOND study. Journal of Neurology. 260(7). 1838–1845. 8 indexed citations
5.
Langdon, Dawn, RHB Benedict, Eva‐Maria Wicklein, K. Beckmann, & S. Fredrikson. (2013). Reports of Patients and Relatives from the CogniCIS Study about Cognition in Clinically Isolated Syndrome: What Are Our Patients Telling Us?. European Neurology. 69(6). 346–351. 5 indexed citations
6.
Goodin, Douglas S., George C. Ebers, Gary Cutter, et al.. (2012). Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study. BMJ Open. 2(6). e001972–e001972. 38 indexed citations
7.
Boyer, David S., Jeffrey S. Heier, David M. Brown, et al.. (2012). Vascular Endothelial Growth Factor Trap-Eye for Macular Edema Secondary to Central Retinal Vein Occlusion. Ophthalmology. 119(5). 1024–1032. 199 indexed citations
8.
Caloyeras, John, Bin Zhang, Cheng Wang, et al.. (2012). Cost-Effectiveness Analysis of Interferon Beta-1b for the Treatment of Patients With a First Clinical Event Suggestive of Multiple Sclerosis. Clinical Therapeutics. 34(5). 1132–1144. 12 indexed citations
9.
10.
Goodin, Douglas S., Anthony Traboulsee, Volker Knappertz, et al.. (2011). Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis. Journal of Neurology Neurosurgery & Psychiatry. 83(3). 282–287. 71 indexed citations
11.
Diana, V., Ursula Schmidt‐Erfurth, Víctor H. González, et al.. (2011). The DA VINCI Study: Phase 2 Primary Results of VEGF Trap-Eye in Patients with Diabetic Macular Edema. Ophthalmology. 118(9). 1819–1826. 201 indexed citations
12.
Ebers, George C., Douglas S. Goodin, Anthony T. Reder, et al.. (2011). Cause of death in patients with multiple sclerosis: The 21-year long-term follow-up study. 2. 1 indexed citations
13.
Ebers, George C., Anthony Traboulsee, Dawn Langdon, et al.. (2010). Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. Journal of Neurology Neurosurgery & Psychiatry. 81(8). 907–912. 92 indexed citations
14.
Ebers, George C., Anthony T. Reder, Anthony Traboulsee, et al.. (2009). Long-term follow-up of the original interferon-β1b trial in multiple sclerosis: Design and lessons from a 16-year observational study. Clinical Therapeutics. 31(8). 1724–1736. 27 indexed citations
15.
Sormani, Maria Pia, Paolo Bruzzi, K. Beckmann, et al.. (2005). The distribution of magnetic resonance imaging response to interferonβ–1b in multiple sclerosis. Journal of Neurology. 252(12). 1455–1458. 19 indexed citations
16.
Rieckmann, Peter, Niels Kruse, Lex Nagelkerken, et al.. (2005). Soluble vascular cell adhesion molecule (VCAM) is associated with treatment effects of Interferon beta-1b in patients with Secondary Progressive Multiple Sclerosis. Journal of Neurology. 252(5). 526–533. 11 indexed citations
17.
Polman, Chris H., Ludwig Kappos, Frank Dahlke, et al.. (2005). Interferon beta-1b treatment does not induce autoantibodies. Neurology. 64(6). 996–1000. 22 indexed citations
18.
Kappos, Ludwig, Chris H. Polman, Carlo Pozzilli, et al.. (2001). Final analysis of the European multicenter trial on IFNβ-1b in secondary-progressive MS. Neurology. 57(11). 1969–1975. 105 indexed citations
19.
Molyneux, P. D., Gareth J. Barker, Frederik Barkhof, et al.. (2001). Clinical–MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. Neurology. 57(12). 2191–2197. 46 indexed citations
20.
Stürzebecher, S, et al.. (1999). Pharmacodynamic Comparison of Single Doses of IFN-beta 1a and IFN-beta 1b in Healthy Volunteers. Journal of Interferon & Cytokine Research. 19(11). 1257–1264. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. Anand Trip Breakdown of academic impact, for papers by HP Hartung Breakdown of academic impact, for papers by Fedor Heidenreich Breakdown of academic impact, for papers by Joaquín Castilló Breakdown of academic impact, for papers by Kathleen Hawker Breakdown of academic impact, for papers by Maureen A. Mealy Breakdown of academic impact, for papers by Joachim Havla Breakdown of academic impact, for papers by Benjamin Brooks Breakdown of academic impact, for papers by Elia Sechi Breakdown of academic impact, for papers by Catherine Agoropoulou
Rankless by CCL
2026